Streetbeat News

Earnings

TRVN

Trevena (NASDAQ:TRVN) reported Q4 earnings with an EPS of $-1.06, missing estimates by -179.0% and a revenue decrease of $81 thousand from the previous year. Despite past earnings misses, the share price increased by 0.0% the day after last quarter's earnings were announced.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 1:40 pm

AEON

AEON Biopharma reported a quarterly loss of $0.71 per share for Q4.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:39 pm

OXM

Oxford Industries' shares dropped following disappointing Q4 financial results and weak Q1 guidance.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:39 pm

ZIMV

ZimVie anticipates reaching over $455M in annualized net sales and a 15%+ adjusted EBITDA margin one year post-deal closure. The company plans to pay down $275M in debt, resulting in a total debt of $234M and an estimated cash reserve of $66M by April 2, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:37 pm

ZIMV

ZimVie Inc. (NASDAQ:ZIMV) has completed the sale of its Spine business to an affiliate of H.I.G. Capital for $375 million, including $315 million in cash and a $60 million promissory note. The sale is part of ZimVie's strategy to focus on the dental market and optimize its structure for shareholder value. Post-sale, ZimVie plans to pay down $275 million of its debt, aiming for a financial profile of $455+ million in Net Sales and a 15%+ adjusted EBITDA margin one year post-closure.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:36 pm

JAGX

Jaguar Health (NASDAQ:JAGX) reported a decrease in Q4 EPS to $0.42 from $0.57 YoY and missed sales estimates with $2.30M against the expected $2.61M, marking a significant decline from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:32 pm

CURV

Torrid Holdings' shares surged following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:31 pm

GUTS

Fractyl Health's shares experienced a decline in trading due to market volatility following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:30 pm

SGRP

SPAR Group's shares surged following the announcement of its Q4 financial results and the sale of its interests in South Africa and Brazil for approximately $22 million.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:18 pm

CYCC

CYCCP

Cyclacel Pharmaceuticals announced it will present new data at the 2024 ASCO Annual Meeting on fadraciclib, a CDK2/9 inhibitor showing promise as a precision medicine for cancer. The CYC065-101 study data supports its development for solid tumors and lymphoma. Fadraciclib has shown activity in various cancers, and the ongoing Phase 1/2 trial is exploring its efficacy further.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:16 pm